Branche, Angela; Rouphael, Nadine; Losada, Cecilia; Baden, Lindsey; Anderson, Evan; Luetkemeyer, Anne; Diemert, David; Winokur, Patricia; Presti, Rachel; Kottkamp, Angelica; Falsey, Ann; Frey, Sharon; Rupp, Richard; Bäcker, Martín; Novak, Richard; Walter, Emmanuel; Jackson, Lisa; Little, Susan; Immergluck, Lilly; Mahgoub, Siham; Whitaker, Jennifer; Babu, Tara; Goepfert, Paul; Fusco, Dahlene; Atmar, Robert; Posavad, Christine; Netzl, Antonia; Smith, Derek; Telu, Kalyani; Mu, Jinjian; Makowski, Mat; Makhene, Mamodikoe; Crandon, Sonja; Montefiori, David; Roberts, Paul; Beigel, John

doi:10.1093/cid/ciad209

Immunogenicity of the BA.1 and BA.4/BA.5 Severe Acute Respiratory Syndrome Coronavirus 2 Bivalent Boosts: Preliminary Results From the COVAIL Randomized Clinical Trial.

Published Web Location

Abstract

In a randomized clinical trial, we compare early neutralizing antibody responses after boosting with bivalent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA (mRNA) vaccines based on either BA.1 or BA.4/BA.5 Omicron spike protein combined with wild-type spike. Responses against SARS-CoV-2 variants exhibited the greatest reduction in titers against currently circulating Omicron subvariants for both bivalent vaccines.

Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.

Main Content

For improved accessibility of PDF content, download the file to your device.

UC San Diego

Immunogenicity of the BA.1 and BA.4/BA.5 Severe Acute Respiratory Syndrome Coronavirus 2 Bivalent Boosts: Preliminary Results From the COVAIL Randomized Clinical Trial.

Published Web Location